Pacira BioSciences, Inc. Common Stock PCRX
Analyst Ratings
- Consensus
- Moderate Buy — 3 Buy · 2 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $29.80 (+29.6% upside)
Key Stats
- Today's Range
- $22.79 – $23.37
- 50-Day Range
- $22.00 – $27.66
- 52-Week Range
- $18.80 – $27.66
- Volume
- 645K shs
- Average Volume
- 643K shs
- Market Cap
- $944.73 million
- P/E Ratio
- 65.71
- Dividend Yield
- —
Valuation
- P/E Ratio
- 65.71
- Price / Book
- 1.41
- Price / Sales
- 1.27
Short Interest
- Short Interest
- 9.32%
- Days to Cover
- 6.90
Financials (TTM)
- Revenue
- $746.16 million
- Net Income
- $14.64 million
- Net Margin
- 1.96%
- Return on Equity
- 2.18%
- Debt-to-Equity
- 0.54
About Pacira BioSciences, Inc. Common Stock
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Related Stocks
Compare head-to-head: PCRX vs LLY·PCRX vs JNJ·PCRX vs ABBV·PCRX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.